Holen Sie sich die Stockscreener-App
19.94
0.86%
0.17
Vorhandelsmarkt:
20.66
0.72
+3.61%
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Assessing Whether Syndax Pharmaceuticals (SNDX) Looks Undervalued After Recent Share Price Weakness - Yahoo Finance
SNDX Reiterates by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Assessing Syndax Pharmaceuticals (SNDX) Valuation After New Revuforj Leukemia Data Spurs Investor Interest - Sahm
Syndax Pharmaceuticals to Present Key Revumenib Data at ASCO 2026, Highlighting Post-Transplant Outcomes and Pharmacokinetic Insights - Quiver Quantitative
Leukemia drug revumenib data to headline 4 ASCO 2026 talks - Stock Titan
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Syndax Pharmaceuticals’ SWOT analysis: stock gains momentum on strong launch - Investing.com UK
Syndax Announces Participation in Upcoming Investor Conferences - 富途牛牛
Which Is a Better Investment, Syndax Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. Stock? - AAII
Point72 (SNDX) reports 1,985,547 shares, 2.3% stake in Syndax - Stock Titan
(SNDX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Does Expanded Revuforj Leukemia Data Set Change The Bull Case For Syndax Pharmaceuticals (SNDX)? - Sahm
Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential - Insider Monkey
UBS Trims Price Target on Syndax Pharmaceuticals to $37 From $38, Maintains Buy Rating - Moomoo
UBS Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $37 - Moomoo
SNDX Maintained by UBS -- Price Target Lowered to $37.00 - GuruFocus
Syndax (SNDX) Highlights Revuforj Data Ahead of EHA Congress - GuruFocus
Syndax Pharmaceuticals stock (US88906L1052): Analyst upgrade drives 6.6% gain - AD HOC NEWS
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition - The Manila Times
Syndax Highlights 12 Revuforj® (revumenib) Abstracts - GlobeNewswire
Leukemia drug revumenib lands 12 studies at European Hematology meeting - Stock Titan
TradingKey - TradingKey
Assessing Syndax Pharmaceuticals (SNDX) Valuation After Stronger Revenue And Narrower Losses - simplywall.st
SNDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Syndax Pharmaceuticals (SNDX): Analyst Ratings Suggest A 92% Upside Potential - DirectorsTalk Interviews
SNDX Stock Price, Quote & Chart | SYNDAX PHARMACEUTICALS INC (NASDAQ:SNDX) - ChartMill
SNDX SEC FilingsSyndax Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Eight new Syndax hires get stock options for 162,100 shares - Stock Titan
MSN Money - MSN
Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $46 - Moomoo
Syndax Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-05-05 - Seeking Alpha
HC Wainwright Has Optimistic Outlook of SNDX Q2 Earnings - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - simplywall.st
(SNDX) Risk Channels and Responsive Allocation - Stock Traders Daily
Biotech Momentum Builds As Syndax Pharmaceuticals Draws Market Attention - Kalkine Media
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Released Its First-Quarter Earnings: Here's What Analysts Think - 富途牛牛
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% Following Analyst Upgrade - MarketBeat
Stifel raises Syndax Pharmaceuticals stock price target on therapy outlook By Investing.com - Investing.com Canada
Stifel raises Syndax Pharmaceuticals stock price target on therapy outlook - Investing.com
HC Wainwright Has Optimistic Outlook of SNDX FY2030 Earnings - MarketBeat
Syndax Pharmaceuticals (SNDX) Is Down 10.7% After Revenue Surges And Loss Narrows In Q1 2026 - simplywall.st
Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives - Sahm
Net current asset value per share of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView
Syndax Pharmaceuticals Q1 Loss Narrows, Revenue Rises - Moomoo
Syndax Pharmaceuticals Reports Over $100 Million in Q1 Combined Sales - HarianBasis.co
Analysts Have Conflicting Sentiments on These Healthcare Companies: Centene (CNC) and Syndax Pharmaceuticals (SNDX) - The Globe and Mail
Jefferies Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $37 - Moomoo
Syndax Pharmaceuticals 1Q Loss $42.7M >SNDX - Moomoo
Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain TractionWhat’s Really Shifting? - Yahoo Finance UK
Syndax Pharmaceuticals Inc ($SNDX) CEO 2025 Pay Revealed - Quiver Quantitative
Stifel raises Syndax Pharmaceuticals stock price target on therapy trajectory By Investing.com - Investing.com Canada
Jefferies cuts Syndax Pharmaceuticals price target on transplant impact By Investing.com - Investing.com Canada
SNDX Maintained by Barclays -- Price Target Raised to $37 - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 7.1%Time to Sell? - MarketBeat
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):